TP53 and cancer: The ASPP1 and ASPP2 CTDs interact with the DNA binding interface of the p53 DBD with affinities in the lower μM range, which involves several residues of the p53 DBD, that are frequently mutated in cancer e.g. R248 (Fig. 1A) [2, 4].